PROSTATE-SPECIFIC ANTIGEN AS A CRITERION OF PROSTATE CANCER PROGRESSION AFTER RADICAL PROSTATECTOMY
- 作者: Varlamov I.S1, Varlamov S.A1, Lazarev A.F1
-
隶属关系:
- 期: 编号 17 (2016)
- 页面: 72-74
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289362
- ID: 289362
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The study was aimed to the development of algorithm to identify the progression of prostate cancer after radical prostatectomy (RPE). The study involved 140 patients with prostate cancer after radical prostatectomy with various degrees of risk for biochemical recurrence, which were under dispensary observation using developed algorithm in the form of monitoring the prostate-specific antigen (PSA) levels every three months. In case of biochemical recurrence with PSA>0.2 ng/mL, bone scintigraphy and magnetic resonance imaging (MRI) of the pelvis with contrast agent were performed. In the case of absence of disease foci, control of PSA levels was continued till level doubling, with subsequent repeat bone scintigraphy and MRI of the pelvis. In case of detection of locoregional or distant foci of the disease, remedial measures were carried out. The proposed algorithm of examination of patients after radical prostatectomy allows to adequate control the risk of disease progression during dispensary observation and provides a 20% reduction in the level of the cost of the examination compared to the standard observation.
全文:
作者简介
I. Varlamov
RSHCI “Altai Regional Oncology Dispensary" SBEIHPE “Altai State Medical University" Barnaul
S. Varlamov
Email: sergei_varlamov@mail.ru
RSHCI “Altai Regional Oncology Dispensary" MD, Head of the Department of Oncourology Barnaul
A. Lazarev
RSHCI “Altai Regional Oncology Dispensary" SBEIHPE “Altai State Medical University" Barnaul
参考
- Матвеев Б.П. Клиническая онкоурология. М., 2011. С. 688.
- Матвеев Б.П. Клиническая онкоурология. М., 2011. С. 582.
- Shao Y.H., Demissie K., Shih W., Mehta A.R., Stein M.N., Roberts C.B., Dipaola R.S., Lu-Yao G.L. Contemporary risk profile of prostate cancer in the United States. J. Natl. Cancer Inst. 2009;101(18):1280-83.
- Yossepowitch O., Eggener S.E., Bianco F.J. Jr, Carver B.S., Serio A., Scardino P.T., Eastham J.A. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J. Urol. 2007;178(2):4939; discussion 499.
- Gerber G.S., Thisted R.A., Chodak G.W., Schroder F.H., Frohmuler H.G., Scardino P.T., Paulson D.F., Middleton A.W. Jr, Rukstalis D.B., Smith J.A. Jr, Ohori M., Theiss M., Schellhammer PF. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. European urology 1997;32(4):385-90.
- Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-56.
- Stephenson A.J., Kattan M.W., Eastham J.A., Bianco F.J., Yossepowitch O., Vickers A.J., Klein E.A., Wood D.P., Scardino P.T. Prostate cancer-specific mortality after radical prostatectome for patients treated in the prostate- specific antigen era. J. Clin. Oncol. 2009;27(26):4300-305.
补充文件
